中国药物经济学Issue(1)：15-19,5.
吉非替尼与厄洛替尼治疗非小细胞肺癌效果的间接比较
Indirect Comparisons for Efficacy of Gefitinib and Erlotinib in Patients with Non-small Cell Lung Cancer
张贺娜 1颜建周 1唐吉锋 1邵蓉1
作者信息
- 1. 中国药科大学医药产业发展研究中心，江苏南京 211198
- 折叠
摘要
Abstract
Objective Systematical y evaluate the efficacy of Gefitinib and Erlotinib in patients with non-smal cel lung cancer(NSCLC). Methods Inputs for the indirect comparisons were chosen from the literature published both in the domestic and overseas about Gefitinib and Erlotinib in patients with NSCLC.Bucher method was used to conduct the indirect comparisons. Results Four literatures about Gefitinib vs standard medicine and three literatures about Erlotinib vs standard medicine were chosen for indirect comparisons.The RR of response rate and disease control rate between Gefitinib and Erlotinib in patients with NSCLC were 0.56(P=0.0536)、0.87(P=0.6745), respectively. The MD of median survival and median progression-free survival were-0.31 (P=0.7718)、-3.93 (P=0.1443), respectively. Conclusion Notwithstanding the limitations of an indirect comparison study,it showed no profound significant differences in efficacy between Gefitinib and Erlotinib in patients with NSCLC.关键词
吉非替尼/厄洛替尼/非小细胞肺癌/间接比较Key words
Gefitinib/Erlotinib/Non-smal cel lung cancer/Indirect comparisons分类
医药卫生引用本文复制引用
张贺娜,颜建周,唐吉锋,邵蓉..吉非替尼与厄洛替尼治疗非小细胞肺癌效果的间接比较[J].中国药物经济学,2013,(1):15-19,5.
